PYXS
Pyxis Oncology, Inc.Company Information
- Company Name
- Pyxis Oncology, Inc.
- CIK
- CIK0001782223
- Category
- <br>Emerging growth company
- Ticker: Exchange
- PYXS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PYXS
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-26
- Last sale
- 2026-06-30
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 35,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 34,028,613
- Shares outstanding
- 63,991,609
- Ownership
- 53.18%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 29.24%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 19 | 6 | 15 | 9 | 11 | 13 | 19 | 12 | 25 | 28 | 10 | 15 | ||||||
| Marketable Securities Current | 14 | 35 | 51 | 67 | 78 | 93 | 107 | 133 | 131 | 129 | 110 | 118 | ||||||
| Restricted Cash Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Receivable Net Current | - | - | - | - | 3 | - | - | - | - | 8 | - | - | ||||||
| Prepaid Expense Current | 2 | 3 | 4 | 5 | 7 | 5 | 4 | 3 | 4 | 6 | 4 | 5 | ||||||
| Assets Current | 37 | 46 | 72 | 83 | 100 | 112 | 132 | 149 | 161 | 172 | 125 | 139 | ||||||
| Property Plant And Equipment Net | 7 | 8 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 11 | 12 | 12 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | 0 | 2 | 2 | 3 | 3 | 24 | 24 | 24 | 24 | 22 | ||||||
| Operating Lease Right Of Use Asset | 11 | 11 | 11 | 12 | 12 | 12 | 12 | - | - | 13 | 13 | 13 | ||||||
| Assets | 55 | 64 | 92 | 106 | 123 | 136 | 157 | 195 | 208 | 220 | 174 | 187 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 5 | 11 | 10 | 9 | 3 | 5 | 5 | 5 | 2 | 4 | 3 | ||||||
| Accrued Liabilities Current | 12 | 10 | 9 | 8 | 7 | 10 | 11 | 14 | 10 | 11 | 13 | 17 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | - | 1 | 1 | 1 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | 8 | 7 | ||||||
| Liabilities Current | 27 | 17 | 21 | 19 | 18 | 14 | 18 | 20 | 17 | 14 | 26 | 28 | ||||||
| Operating Lease Liability Noncurrent | 16 | 16 | 17 | 17 | 18 | 18 | 19 | 19 | 19 | 20 | 20 | 20 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Liabilities | 43 | 33 | 38 | 37 | 36 | 33 | 36 | 42 | 39 | 36 | 48 | 49 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | 0 | 2 | 2 | 2 | 2 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 503 | 498 | 496 | 494 | 491 | 488 | 484 | 481 | 477 | 474 | 412 | 409 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -492 | -466 | -443 | -425 | -403 | -385 | -364 | -328 | -307 | -289 | -286 | -271 | ||||||
| Stockholders Equity | 11 | 31 | 53 | 69 | 88 | 103 | 121 | 154 | 170 | 184 | 126 | 138 | ||||||
| Liabilities And Stockholders Equity | 55 | 64 | 92 | 106 | 123 | 136 | 157 | 195 | 208 | 220 | 174 | 187 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 190 | 190 | 190 | 190 | 190 | 190 | 190 | 190 | 190 | 190 | 190 | 190 | ||||||
| Common Stock Shares Issued | 63 | 63 | 63 | 62 | 62 | 62 | 60 | 59 | 59 | 59 | 45 | 44 | ||||||
| Shares Outstanding | 63 | 63 | 63 | 62 | 62 | 62 | 60 | 59 | 59 | 59 | 45 | 44 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPyxis Oncology, Inc. (PYXS) — SEC Financial Statements & Analysis
Pyxis Oncology, Inc. (PYXS) is a pharmaceutical preparations company, incorporated in DE. Pyxis Oncology, Inc. trades on Nasdaq as: PYXS. Pyxis Oncology, Inc. (PYXS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Pyxis Oncology, Inc. carries a market cap of $192.61M, a P/E ratio of -2.17x, a P/B ratio of 16.84x, a P/S ratio of 17.45x, an enterprise value of $173.76M, and an EV/EBITDA multiple of -1.98x. On profitability, it posts an operating margin of -834.44%, a net margin of -803.83%, a Return on Equity (ROE) of -179.10%, a Return on Assets (ROA) of -99.62%, and a Return on Invested Capital (ROIC) of -149.68%. Per share, it reports EPS of $-1.39, diluted EPS of $-1.39, free cash flow per share of $-1.06, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 291.42% year-over-year, net income growth of -7.85% year-over-year, and EPS growth of -10.84% year-over-year. On the balance sheet, it maintains a current ratio of 1.34x, a quick ratio of 1.25x, working capital of $9.26M, a debt-to-equity ratio of 3.80x, a debt ratio of 0.79, free cash flow of $-67.92M (TTM), and net debt of $-18.86M. Figures sourced from SEC EDGAR.
- Market Cap
- $192.61M
- P/E TTM
- -2.17x
- EPS TTM
- $-1.39
- P/B TTM
- 16.84x
- ROE TTM
- -179.10%
- ROA TTM
- -99.62%
- Debt To Equity
- 3.80x
- Free Cash Flow TTM
- $-67.92M
- Net Revenue TTM Growth 1Y
- 291.42%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Pyxis Oncology, Inc. in?
Pyxis Oncology, Inc. (PYXS) operates in the Pharmaceutical Preparations industry.
What exchange does PYXS trade on?
Pyxis Oncology, Inc. (PYXS) trades on the Nasdaq.
Where is Pyxis Oncology, Inc. incorporated?
Pyxis Oncology, Inc. is incorporated in DE.
When was Pyxis Oncology, Inc. (PYXS)'s most recent SEC filing?
Pyxis Oncology, Inc. (PYXS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is PYXS's market cap?
Pyxis Oncology, Inc. (PYXS) has a market capitalization of $192.61M as of 2026-06-30.
What is PYXS's EPS (earnings per share)?
Pyxis Oncology, Inc. (PYXS)'s trailing twelve month EPS is $-1.39 as of 2026-06-30.
What is PYXS's ROE (return on equity)?
Pyxis Oncology, Inc. (PYXS)'s trailing twelve month Return on Equity (ROE) is -179.10% as of 2026-06-30.
What is PYXS's ROA (return on assets)?
Pyxis Oncology, Inc. (PYXS)'s trailing twelve month Return on Assets (ROA) is -99.62% as of 2026-06-30.
What is PYXS's ROIC (return on invested capital)?
Pyxis Oncology, Inc. (PYXS)'s trailing twelve month Return on Invested Capital (ROIC) is -149.68% as of 2026-03-31.
What is PYXS's EV/EBITDA?
Pyxis Oncology, Inc. (PYXS)'s trailing twelve month EV/EBITDA is -1.98x as of 2026-06-30.